Eli Lilly 4 juin 2026 Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership - Pharmaceutical Technology
Eli Lilly 4 juin 2026 Eli Lilly forms billion-dollar genetic kidney disease partnership with US biotech Ascidian Therapeutics - medwatch.com
Eli Lilly 3 juin 2026 Lilly, Boehringer to slash at least $1B each from planned investments in Germany - Fierce Pharma
Eli Lilly 1 juin 2026 Lilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclear - Fierce Biotech
Eli Lilly 28 mai 2026 Eli Lilly Stock Heads for Record Close. CVS Weight-Loss Drug Coverage Drives It Higher. - Barron's
Eli Lilly 28 mai 2026 CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo - Fierce Pharma
Eli Lilly 26 mai 2026 Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues - Fierce Biotech
Eli Lilly 26 mai 2026 Lilly announces three acquisitions to build infectious disease portfolio | Eli Lilly and Company - investor.lilly.com
Eli Lilly 25 mai 2026 Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study - statnews.com
Eli Lilly 25 mai 2026 A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia - PR Newswire
Eli Lilly 25 mai 2026 Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors - Fierce Biotech
Eli Lilly 21 mai 2026 Lilly’s triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile - Fierce Biotech
Eli Lilly 21 mai 2026 Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial | Eli Lilly and Company - investor.lilly.com
Eli Lilly 21 mai 2026 Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling - BioSpace